Uprima is the drug for the treatment of erectile dysfunction (ED), which were available on sale in Europe for several years.
Supplier of Uprima tablets was the company Abbott Laboratories.
The company received a centralized European authorization for Uprima tablets in 2001. In just 5 years after the start of sales, Abbott has refused to extend the European authorization for Uprima, and this drug was withdrawn from the market.
In 2002, the cost of one 3mg Uprima tablet was approximately 10 euro. For comparison, Viagra 100mg was sold in 2002 at a price of about 12 euro per pill.
Despite the relatively low cost of Uprima tablets, Abbott company failed to make them a bestseller. A key reason for the unsuccessful launch of Uprima sales was their low efficiency.
Abbott voluntarily recalled Uprima drug from the European market, and, thus, admitted the defeat in the competition with the manufacturer of Viagra tablets.
Uprima drug had several distinctive features that made it differ from any other drug for the ED treatment
If we evaluate the efficiency of Uprima by the results of clinical trials, we can include it in the list of 10 best products for the treatment of erectile dysfunction.
However, the analyses of post-marketing study results brought the opposite conclusion. As it turned out, every second man, who was taking an Uprima dose of 2 mg or 3 mg was not able to achieve and maintain an erection sufficient for a successful sexual intercourse.
By increasing the dose of Uprima to 5 mg or 6 mg, the number of successful intercourse increased. At that, the frequency and severity of side effects also increased. Therefore, Uprima doses above 3mg were prescribed very rarely.
After numerous negative reviews about Uprima, doctors stopped prescribing this drug to men, and its sales began to decline in a fast pace. Gradually, Uprima tablets disappeared from the shelves of pharmacies, and today only health professionals remember about this drug.